Ocular Therapeutix, Inc.
Get $10 bonus on your first $100 deposit for OCUL
Get $10 bonus on your first $100 deposit for OCUL
Ocular Therapeutix, Inc. (OCUL) Stock Competitors & Peer Comparison
See (OCUL) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| OCUL | $7.97 | -6.12% | 1.8B | -5.68 | -$1.42 | N/A |
| VRTX | $428.43 | -2.34% | 110.3B | 28.37 | $15.31 | N/A |
| REGN | $751.96 | -1.30% | 79.3B | 18.41 | $41.44 | +0.47% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $739.46 | -0.93% | 46.3B | 38.25 | $19.56 | N/A |
| ALNY | $315.99 | -0.90% | 43.8B | 141.78 | $2.33 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| INSM | $160.64 | -1.10% | 35.3B | -25.52 | -$6.42 | N/A |
| UTHR | $558.56 | -1.11% | 24.5B | 20.10 | $27.84 | N/A |
| BNTX | $89.06 | -2.33% | 22.9B | -16.78 | -$5.44 | N/A |
Stock Comparison
OCUL vs VRTX Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, VRTX has a market cap of 110.3B. Regarding current trading prices, OCUL is priced at $7.97, while VRTX trades at $428.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas VRTX's P/E ratio is 28.37. In terms of profitability, OCUL's ROE is -0.72%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, OCUL is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check VRTX's competition here
OCUL vs REGN Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, REGN has a market cap of 79.3B. Regarding current trading prices, OCUL is priced at $7.97, while REGN trades at $751.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas REGN's P/E ratio is 18.41. In terms of profitability, OCUL's ROE is -0.72%, compared to REGN's ROE of +0.15%. Regarding short-term risk, OCUL is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check REGN's competition here
OCUL vs VRNA Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, OCUL is priced at $7.97, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas VRNA's P/E ratio is -102.80. In terms of profitability, OCUL's ROE is -0.72%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, OCUL is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check VRNA's competition here
OCUL vs ARGX Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, ARGX has a market cap of 46.3B. Regarding current trading prices, OCUL is priced at $7.97, while ARGX trades at $739.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas ARGX's P/E ratio is 38.25. In terms of profitability, OCUL's ROE is -0.72%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, OCUL is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check ARGX's competition here
OCUL vs ALNY Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, ALNY has a market cap of 43.8B. Regarding current trading prices, OCUL is priced at $7.97, while ALNY trades at $315.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas ALNY's P/E ratio is 141.78. In terms of profitability, OCUL's ROE is -0.72%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, OCUL is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check ALNY's competition here
OCUL vs SGEN Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, OCUL is priced at $7.97, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas SGEN's P/E ratio is -57.19. In terms of profitability, OCUL's ROE is -0.72%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, OCUL is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check SGEN's competition here
OCUL vs INSM Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, INSM has a market cap of 35.3B. Regarding current trading prices, OCUL is priced at $7.97, while INSM trades at $160.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas INSM's P/E ratio is -25.52. In terms of profitability, OCUL's ROE is -0.72%, compared to INSM's ROE of -1.68%. Regarding short-term risk, OCUL is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check INSM's competition here
OCUL vs UTHR Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, UTHR has a market cap of 24.5B. Regarding current trading prices, OCUL is priced at $7.97, while UTHR trades at $558.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas UTHR's P/E ratio is 20.10. In terms of profitability, OCUL's ROE is -0.72%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, OCUL is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check UTHR's competition here
OCUL vs BNTX Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, OCUL is priced at $7.97, while BNTX trades at $89.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas BNTX's P/E ratio is -16.78. In terms of profitability, OCUL's ROE is -0.72%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, OCUL is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check BNTX's competition here
OCUL vs RPRX Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, RPRX has a market cap of 20.3B. Regarding current trading prices, OCUL is priced at $7.97, while RPRX trades at $46.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas RPRX's P/E ratio is 26.58. In terms of profitability, OCUL's ROE is -0.72%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, OCUL is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check RPRX's competition here
OCUL vs BGNE Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, OCUL is priced at $7.97, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas BGNE's P/E ratio is -22.55. In terms of profitability, OCUL's ROE is -0.72%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, OCUL is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check BGNE's competition here
OCUL vs ROIV Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, ROIV has a market cap of 20B. Regarding current trading prices, OCUL is priced at $7.97, while ROIV trades at $27.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas ROIV's P/E ratio is -23.83. In terms of profitability, OCUL's ROE is -0.72%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, OCUL is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check ROIV's competition here
OCUL vs MRNA Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, MRNA has a market cap of 19.3B. Regarding current trading prices, OCUL is priced at $7.97, while MRNA trades at $48.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas MRNA's P/E ratio is -6.72. In terms of profitability, OCUL's ROE is -0.72%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, OCUL is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check MRNA's competition here
OCUL vs RVMD Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, RVMD has a market cap of 18.9B. Regarding current trading prices, OCUL is priced at $7.97, while RVMD trades at $94.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas RVMD's P/E ratio is -16.05. In terms of profitability, OCUL's ROE is -0.72%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, OCUL is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check RVMD's competition here
OCUL vs INCY Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, INCY has a market cap of 18.9B. Regarding current trading prices, OCUL is priced at $7.97, while INCY trades at $93.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas INCY's P/E ratio is 14.80. In terms of profitability, OCUL's ROE is -0.72%, compared to INCY's ROE of +0.29%. Regarding short-term risk, OCUL is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check INCY's competition here
OCUL vs DNA-WT Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, OCUL is priced at $7.97, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, OCUL's ROE is -0.72%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, OCUL is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check DNA-WT's competition here
OCUL vs GMAB Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, GMAB has a market cap of 17.1B. Regarding current trading prices, OCUL is priced at $7.97, while GMAB trades at $26.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas GMAB's P/E ratio is 18.02. In terms of profitability, OCUL's ROE is -0.72%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, OCUL is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check GMAB's competition here
OCUL vs BBIO Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, BBIO has a market cap of 14B. Regarding current trading prices, OCUL is priced at $7.97, while BBIO trades at $70.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas BBIO's P/E ratio is -19.12. In terms of profitability, OCUL's ROE is -0.72%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, OCUL is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check BBIO's competition here
OCUL vs ASND Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, ASND has a market cap of 13.9B. Regarding current trading prices, OCUL is priced at $7.97, while ASND trades at $221.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas ASND's P/E ratio is -51.99. In terms of profitability, OCUL's ROE is -0.72%, compared to ASND's ROE of +1.28%. Regarding short-term risk, OCUL is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check ASND's competition here
OCUL vs SMMT Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, SMMT has a market cap of 13.9B. Regarding current trading prices, OCUL is priced at $7.97, while SMMT trades at $18.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas SMMT's P/E ratio is -12.98. In terms of profitability, OCUL's ROE is -0.72%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, OCUL is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check SMMT's competition here
OCUL vs KRTX Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, OCUL is priced at $7.97, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas KRTX's P/E ratio is -28.09. In terms of profitability, OCUL's ROE is -0.72%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, OCUL is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check KRTX's competition here
OCUL vs IONS Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, IONS has a market cap of 12.3B. Regarding current trading prices, OCUL is priced at $7.97, while IONS trades at $73.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas IONS's P/E ratio is -31.23. In terms of profitability, OCUL's ROE is -0.72%, compared to IONS's ROE of -0.69%. Regarding short-term risk, OCUL is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check IONS's competition here
OCUL vs MDGL Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, MDGL has a market cap of 12.2B. Regarding current trading prices, OCUL is priced at $7.97, while MDGL trades at $522.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas MDGL's P/E ratio is -41.55. In terms of profitability, OCUL's ROE is -0.72%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, OCUL is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check MDGL's competition here
OCUL vs EXEL Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, EXEL has a market cap of 11.8B. Regarding current trading prices, OCUL is priced at $7.97, while EXEL trades at $43.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas EXEL's P/E ratio is 15.82. In terms of profitability, OCUL's ROE is -0.72%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, OCUL is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check EXEL's competition here
OCUL vs JAZZ Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, JAZZ has a market cap of 11.5B. Regarding current trading prices, OCUL is priced at $7.97, while JAZZ trades at $185.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas JAZZ's P/E ratio is -32.05. In terms of profitability, OCUL's ROE is -0.72%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, OCUL is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check JAZZ's competition here
OCUL vs RNAM Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, OCUL is priced at $7.97, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas RNAM's P/E ratio is -17.39. In terms of profitability, OCUL's ROE is -0.72%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, OCUL is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check RNAM's competition here
OCUL vs BMRN Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, BMRN has a market cap of 10.8B. Regarding current trading prices, OCUL is priced at $7.97, while BMRN trades at $55.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas BMRN's P/E ratio is 31.23. In terms of profitability, OCUL's ROE is -0.72%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, OCUL is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check BMRN's competition here
OCUL vs RXDX Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, OCUL is priced at $7.97, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas RXDX's P/E ratio is -56.47. In terms of profitability, OCUL's ROE is -0.72%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, OCUL is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check RXDX's competition here
OCUL vs IMGN Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, OCUL is priced at $7.97, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas IMGN's P/E ratio is -111.55. In terms of profitability, OCUL's ROE is -0.72%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, OCUL is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check IMGN's competition here
OCUL vs AXSM Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, AXSM has a market cap of 8.7B. Regarding current trading prices, OCUL is priced at $7.97, while AXSM trades at $166.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas AXSM's P/E ratio is -46.25. In terms of profitability, OCUL's ROE is -0.72%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, OCUL is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check AXSM's competition here
OCUL vs PCVX Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, PCVX has a market cap of 8.6B. Regarding current trading prices, OCUL is priced at $7.97, while PCVX trades at $58.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas PCVX's P/E ratio is -10.63. In terms of profitability, OCUL's ROE is -0.72%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, OCUL is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check PCVX's competition here
OCUL vs ARWR Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, ARWR has a market cap of 8.6B. Regarding current trading prices, OCUL is priced at $7.97, while ARWR trades at $59.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas ARWR's P/E ratio is 38.20. In terms of profitability, OCUL's ROE is -0.72%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, OCUL is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check ARWR's competition here
OCUL vs TECH Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, TECH has a market cap of 8.4B. Regarding current trading prices, OCUL is priced at $7.97, while TECH trades at $53.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas TECH's P/E ratio is 101.51. In terms of profitability, OCUL's ROE is -0.72%, compared to TECH's ROE of +0.04%. Regarding short-term risk, OCUL is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check TECH's competition here
OCUL vs BPMC Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, OCUL is priced at $7.97, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas BPMC's P/E ratio is -51.58. In terms of profitability, OCUL's ROE is -0.72%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, OCUL is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check BPMC's competition here
OCUL vs CERE Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, OCUL is priced at $7.97, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas CERE's P/E ratio is -16.47. In terms of profitability, OCUL's ROE is -0.72%, compared to CERE's ROE of -0.72%. Regarding short-term risk, OCUL is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check CERE's competition here
OCUL vs CYTK Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, CYTK has a market cap of 8B. Regarding current trading prices, OCUL is priced at $7.97, while CYTK trades at $64.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas CYTK's P/E ratio is -9.93. In terms of profitability, OCUL's ROE is -0.72%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, OCUL is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check CYTK's competition here
OCUL vs ABVX Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, ABVX has a market cap of 7.8B. Regarding current trading prices, OCUL is priced at $7.97, while ABVX trades at $115.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas ABVX's P/E ratio is -21.39. In terms of profitability, OCUL's ROE is -0.72%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, OCUL is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check ABVX's competition here
OCUL vs KRYS Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, KRYS has a market cap of 7.7B. Regarding current trading prices, OCUL is priced at $7.97, while KRYS trades at $258.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas KRYS's P/E ratio is 38.33. In terms of profitability, OCUL's ROE is -0.72%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, OCUL is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check KRYS's competition here
OCUL vs NUVL Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, NUVL has a market cap of 7.6B. Regarding current trading prices, OCUL is priced at $7.97, while NUVL trades at $102.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas NUVL's P/E ratio is -17.73. In terms of profitability, OCUL's ROE is -0.72%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, OCUL is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check NUVL's competition here
OCUL vs HALO Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, HALO has a market cap of 7.4B. Regarding current trading prices, OCUL is priced at $7.97, while HALO trades at $62.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas HALO's P/E ratio is 24.64. In terms of profitability, OCUL's ROE is -0.72%, compared to HALO's ROE of +0.93%. Regarding short-term risk, OCUL is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check HALO's competition here
OCUL vs MTSR Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, OCUL is priced at $7.97, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas MTSR's P/E ratio is -23.58. In terms of profitability, OCUL's ROE is -0.72%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, OCUL is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check MTSR's competition here
OCUL vs IBRX Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, IBRX has a market cap of 7.3B. Regarding current trading prices, OCUL is priced at $7.97, while IBRX trades at $6.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas IBRX's P/E ratio is -18.63. In terms of profitability, OCUL's ROE is -0.72%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, OCUL is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check IBRX's competition here
OCUL vs KYMR Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, KYMR has a market cap of 7B. Regarding current trading prices, OCUL is priced at $7.97, while KYMR trades at $83.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas KYMR's P/E ratio is -23.11. In terms of profitability, OCUL's ROE is -0.72%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, OCUL is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check KYMR's competition here
OCUL vs MRUS Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, OCUL is priced at $7.97, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas MRUS's P/E ratio is -17.05. In terms of profitability, OCUL's ROE is -0.72%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, OCUL is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check MRUS's competition here
OCUL vs BLTE Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, BLTE has a market cap of 6.7B. Regarding current trading prices, OCUL is priced at $7.97, while BLTE trades at $168.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas BLTE's P/E ratio is -74.42. In terms of profitability, OCUL's ROE is -0.72%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, OCUL is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check BLTE's competition here
OCUL vs ACLX Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, OCUL is priced at $7.97, while ACLX trades at $114.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas ACLX's P/E ratio is -28.19. In terms of profitability, OCUL's ROE is -0.72%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, OCUL is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check ACLX's competition here
OCUL vs RETA Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, OCUL is priced at $7.97, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas RETA's P/E ratio is -66.29. In terms of profitability, OCUL's ROE is -0.72%, compared to RETA's ROE of +0.47%. Regarding short-term risk, OCUL is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check RETA's competition here
OCUL vs PTGX Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, PTGX has a market cap of 6.6B. Regarding current trading prices, OCUL is priced at $7.97, while PTGX trades at $102.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas PTGX's P/E ratio is -50.19. In terms of profitability, OCUL's ROE is -0.72%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, OCUL is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check PTGX's competition here
OCUL vs PRAX Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, PRAX has a market cap of 6.6B. Regarding current trading prices, OCUL is priced at $7.97, while PRAX trades at $303.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas PRAX's P/E ratio is -23.02. In terms of profitability, OCUL's ROE is -0.72%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, OCUL is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check PRAX's competition here
OCUL vs RYTM Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, RYTM has a market cap of 5.9B. Regarding current trading prices, OCUL is priced at $7.97, while RYTM trades at $85.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas RYTM's P/E ratio is -27.96. In terms of profitability, OCUL's ROE is -0.72%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, OCUL is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check RYTM's competition here
OCUL vs COGT Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, COGT has a market cap of 5.7B. Regarding current trading prices, OCUL is priced at $7.97, while COGT trades at $34.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas COGT's P/E ratio is -16.40. In terms of profitability, OCUL's ROE is -0.72%, compared to COGT's ROE of -1.00%. Regarding short-term risk, OCUL is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check COGT's competition here
OCUL vs CGON Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, CGON has a market cap of 5.7B. Regarding current trading prices, OCUL is priced at $7.97, while CGON trades at $68.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas CGON's P/E ratio is -32.48. In terms of profitability, OCUL's ROE is -0.72%, compared to CGON's ROE of -0.23%. Regarding short-term risk, OCUL and CGON have similar daily volatility (1.55).Check CGON's competition here
OCUL vs PTCT Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, PTCT has a market cap of 5.7B. Regarding current trading prices, OCUL is priced at $7.97, while PTCT trades at $68.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas PTCT's P/E ratio is 8.03. In terms of profitability, OCUL's ROE is -0.72%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, OCUL is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check PTCT's competition here
OCUL vs ALKS Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, ALKS has a market cap of 5.7B. Regarding current trading prices, OCUL is priced at $7.97, while ALKS trades at $33.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas ALKS's P/E ratio is 23.83. In terms of profitability, OCUL's ROE is -0.72%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, OCUL is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check ALKS's competition here
OCUL vs CDTX Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, OCUL is priced at $7.97, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas CDTX's P/E ratio is -19.77. In terms of profitability, OCUL's ROE is -0.72%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, OCUL is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check CDTX's competition here
OCUL vs SRRK Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, SRRK has a market cap of 5.6B. Regarding current trading prices, OCUL is priced at $7.97, while SRRK trades at $47.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas SRRK's P/E ratio is -14.84. In terms of profitability, OCUL's ROE is -0.72%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, OCUL is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check SRRK's competition here
OCUL vs ABCM Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, OCUL is priced at $7.97, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, OCUL's ROE is -0.72%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, OCUL is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check ABCM's competition here
OCUL vs CELC Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, CELC has a market cap of 5.5B. Regarding current trading prices, OCUL is priced at $7.97, while CELC trades at $113.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas CELC's P/E ratio is -30.14. In terms of profitability, OCUL's ROE is -0.72%, compared to CELC's ROE of -2.03%. Regarding short-term risk, OCUL is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check CELC's competition here
OCUL vs ISEE Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, OCUL is priced at $7.97, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas ISEE's P/E ratio is -22.44. In terms of profitability, OCUL's ROE is -0.72%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, OCUL is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check ISEE's competition here
OCUL vs TGTX Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, TGTX has a market cap of 5.4B. Regarding current trading prices, OCUL is priced at $7.97, while TGTX trades at $33.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas TGTX's P/E ratio is 12.16. In terms of profitability, OCUL's ROE is -0.72%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, OCUL is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check TGTX's competition here
OCUL vs CAI Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, CAI has a market cap of 5.4B. Regarding current trading prices, OCUL is priced at $7.97, while CAI trades at $18.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas CAI's P/E ratio is -5.90. In terms of profitability, OCUL's ROE is -0.72%, compared to CAI's ROE of +0.25%. Regarding short-term risk, OCUL is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check CAI's competition here
OCUL vs FBIOX Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, FBIOX has a market cap of 5.4B. Regarding current trading prices, OCUL is priced at $7.97, while FBIOX trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas FBIOX's P/E ratio is N/A. In terms of profitability, OCUL's ROE is -0.72%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, OCUL is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check FBIOX's competition here
OCUL vs CNTA Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, CNTA has a market cap of 5.3B. Regarding current trading prices, OCUL is priced at $7.97, while CNTA trades at $39.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas CNTA's P/E ratio is -27.17. In terms of profitability, OCUL's ROE is -0.72%, compared to CNTA's ROE of -0.51%. Regarding short-term risk, OCUL is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check CNTA's competition here
OCUL vs ERAS Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, ERAS has a market cap of 5.3B. Regarding current trading prices, OCUL is priced at $7.97, while ERAS trades at $16.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas ERAS's P/E ratio is -38.91. In terms of profitability, OCUL's ROE is -0.72%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, OCUL is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check ERAS's competition here
OCUL vs APLS Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, APLS has a market cap of 5.2B. Regarding current trading prices, OCUL is priced at $7.97, while APLS trades at $40.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas APLS's P/E ratio is 225.72. In terms of profitability, OCUL's ROE is -0.72%, compared to APLS's ROE of +0.08%. Regarding short-term risk, OCUL is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check APLS's competition here
OCUL vs IMVT Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, IMVT has a market cap of 5.1B. Regarding current trading prices, OCUL is priced at $7.97, while IMVT trades at $24.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas IMVT's P/E ratio is -9.32. In terms of profitability, OCUL's ROE is -0.72%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, OCUL is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check IMVT's competition here
OCUL vs MIRM Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, MIRM has a market cap of 4.8B. Regarding current trading prices, OCUL is priced at $7.97, while MIRM trades at $94.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas MIRM's P/E ratio is -204.77. In terms of profitability, OCUL's ROE is -0.72%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, OCUL is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check MIRM's competition here
OCUL vs TERN Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, OCUL is priced at $7.97, while TERN trades at $52.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas TERN's P/E ratio is -51.24. In terms of profitability, OCUL's ROE is -0.72%, compared to TERN's ROE of -0.20%. Regarding short-term risk, OCUL is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check TERN's competition here
OCUL vs CRSP Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, CRSP has a market cap of 4.7B. Regarding current trading prices, OCUL is priced at $7.97, while CRSP trades at $48.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas CRSP's P/E ratio is -7.60. In terms of profitability, OCUL's ROE is -0.72%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, OCUL is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check CRSP's competition here
OCUL vs APGE Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, APGE has a market cap of 4.7B. Regarding current trading prices, OCUL is priced at $7.97, while APGE trades at $82.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas APGE's P/E ratio is -19.91. In terms of profitability, OCUL's ROE is -0.72%, compared to APGE's ROE of -0.37%. Regarding short-term risk, OCUL is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check APGE's competition here
OCUL vs FOLD Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, OCUL is priced at $7.97, while FOLD trades at $14.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas FOLD's P/E ratio is -160.56. In terms of profitability, OCUL's ROE is -0.72%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, OCUL is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check FOLD's competition here
OCUL vs AKRO Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, OCUL is priced at $7.97, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas AKRO's P/E ratio is -14.57. In terms of profitability, OCUL's ROE is -0.72%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, OCUL is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check AKRO's competition here
OCUL vs XENE Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, XENE has a market cap of 4.5B. Regarding current trading prices, OCUL is priced at $7.97, while XENE trades at $56.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas XENE's P/E ratio is -13.03. In terms of profitability, OCUL's ROE is -0.72%, compared to XENE's ROE of -0.56%. Regarding short-term risk, OCUL is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check XENE's competition here
OCUL vs ALPN Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, OCUL is priced at $7.97, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas ALPN's P/E ratio is -101.52. In terms of profitability, OCUL's ROE is -0.72%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, OCUL is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check ALPN's competition here
OCUL vs CORT Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, CORT has a market cap of 4.3B. Regarding current trading prices, OCUL is priced at $7.97, while CORT trades at $40.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas CORT's P/E ratio is 49.82. In terms of profitability, OCUL's ROE is -0.72%, compared to CORT's ROE of +0.15%. Regarding short-term risk, OCUL is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check CORT's competition here
OCUL vs OPT Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, OCUL is priced at $7.97, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas OPT's P/E ratio is -1.52. In terms of profitability, OCUL's ROE is -0.72%, compared to OPT's ROE of +0.88%. Regarding short-term risk, OCUL is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check OPT's competition here
OCUL vs MRTX Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, OCUL is priced at $7.97, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas MRTX's P/E ratio is -4.82. In terms of profitability, OCUL's ROE is -0.72%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, OCUL is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check MRTX's competition here
OCUL vs LGND Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, LGND has a market cap of 4.1B. Regarding current trading prices, OCUL is priced at $7.97, while LGND trades at $202.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas LGND's P/E ratio is 33.16. In terms of profitability, OCUL's ROE is -0.72%, compared to LGND's ROE of +0.14%. Regarding short-term risk, OCUL is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check LGND's competition here
OCUL vs CRNX Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, CRNX has a market cap of 3.9B. Regarding current trading prices, OCUL is priced at $7.97, while CRNX trades at $36.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas CRNX's P/E ratio is -7.62. In terms of profitability, OCUL's ROE is -0.72%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, OCUL is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check CRNX's competition here
OCUL vs NAMS Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, NAMS has a market cap of 3.9B. Regarding current trading prices, OCUL is priced at $7.97, while NAMS trades at $33.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas NAMS's P/E ratio is -19.84. In terms of profitability, OCUL's ROE is -0.72%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, OCUL is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check NAMS's competition here
OCUL vs VKTX Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, VKTX has a market cap of 3.9B. Regarding current trading prices, OCUL is priced at $7.97, while VKTX trades at $33.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas VKTX's P/E ratio is -10.64. In terms of profitability, OCUL's ROE is -0.72%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, OCUL is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check VKTX's competition here
OCUL vs ACAD Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, OCUL is priced at $7.97, while ACAD trades at $22.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas ACAD's P/E ratio is 9.70. In terms of profitability, OCUL's ROE is -0.72%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, OCUL is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check ACAD's competition here
OCUL vs RYZB Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, OCUL is priced at $7.97, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas RYZB's P/E ratio is -57.86. In terms of profitability, OCUL's ROE is -0.72%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, OCUL is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check RYZB's competition here
OCUL vs CBAY Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, OCUL is priced at $7.97, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas CBAY's P/E ratio is -32.81. In terms of profitability, OCUL's ROE is -0.72%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, OCUL is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check CBAY's competition here
OCUL vs KNSA Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, KNSA has a market cap of 3.7B. Regarding current trading prices, OCUL is priced at $7.97, while KNSA trades at $49.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas KNSA's P/E ratio is 66.07. In terms of profitability, OCUL's ROE is -0.72%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, OCUL is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check KNSA's competition here
OCUL vs SWTX Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, OCUL is priced at $7.97, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas SWTX's P/E ratio is -13.78. In terms of profitability, OCUL's ROE is -0.72%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, OCUL is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check SWTX's competition here
OCUL vs EWTX Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, EWTX has a market cap of 3.5B. Regarding current trading prices, OCUL is priced at $7.97, while EWTX trades at $32.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas EWTX's P/E ratio is -20.14. In terms of profitability, OCUL's ROE is -0.72%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, OCUL is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check EWTX's competition here
OCUL vs LEGN Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, LEGN has a market cap of 3.5B. Regarding current trading prices, OCUL is priced at $7.97, while LEGN trades at $18.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas LEGN's P/E ratio is -11.53. In terms of profitability, OCUL's ROE is -0.72%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, OCUL is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check LEGN's competition here
OCUL vs LQDA Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, LQDA has a market cap of 3.3B. Regarding current trading prices, OCUL is priced at $7.97, while LQDA trades at $37.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas LQDA's P/E ratio is -47.06. In terms of profitability, OCUL's ROE is -0.72%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, OCUL is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check LQDA's competition here
OCUL vs DNTH Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, DNTH has a market cap of 3.3B. Regarding current trading prices, OCUL is priced at $7.97, while DNTH trades at $84.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas DNTH's P/E ratio is -20.36. In terms of profitability, OCUL's ROE is -0.72%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, OCUL is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check DNTH's competition here
OCUL vs TLX Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, TLX has a market cap of 3.1B. Regarding current trading prices, OCUL is priced at $7.97, while TLX trades at $9.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas TLX's P/E ratio is -454.50. In terms of profitability, OCUL's ROE is -0.72%, compared to TLX's ROE of -0.02%. Regarding short-term risk, OCUL is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check TLX's competition here
OCUL vs DNLI Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, DNLI has a market cap of 3.1B. Regarding current trading prices, OCUL is priced at $7.97, while DNLI trades at $19.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas DNLI's P/E ratio is -6.53. In terms of profitability, OCUL's ROE is -0.72%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, OCUL is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check DNLI's competition here
OCUL vs CPRX Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, CPRX has a market cap of 3.1B. Regarding current trading prices, OCUL is priced at $7.97, while CPRX trades at $24.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas CPRX's P/E ratio is 14.87. In terms of profitability, OCUL's ROE is -0.72%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, OCUL is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check CPRX's competition here
OCUL vs DYN Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, DYN has a market cap of 3B. Regarding current trading prices, OCUL is priced at $7.97, while DYN trades at $17.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas DYN's P/E ratio is -5.29. In terms of profitability, OCUL's ROE is -0.72%, compared to DYN's ROE of -0.61%. Regarding short-term risk, OCUL is more volatile compared to DYN. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check DYN's competition here
OCUL vs TARS Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, TARS has a market cap of 3B. Regarding current trading prices, OCUL is priced at $7.97, while TARS trades at $68.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas TARS's P/E ratio is -44.14. In terms of profitability, OCUL's ROE is -0.72%, compared to TARS's ROE of -0.20%. Regarding short-term risk, OCUL is less volatile compared to TARS. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check TARS's competition here
OCUL vs GPCR Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, GPCR has a market cap of 3B. Regarding current trading prices, OCUL is priced at $7.97, while GPCR trades at $50.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas GPCR's P/E ratio is -21.57. In terms of profitability, OCUL's ROE is -0.72%, compared to GPCR's ROE of -0.15%. Regarding short-term risk, OCUL is less volatile compared to GPCR. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check GPCR's competition here
OCUL vs SYRE Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, SYRE has a market cap of 3B. Regarding current trading prices, OCUL is priced at $7.97, while SYRE trades at $49.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas SYRE's P/E ratio is -24.74. In terms of profitability, OCUL's ROE is -0.72%, compared to SYRE's ROE of -0.29%. Regarding short-term risk, OCUL is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for OCUL.Check SYRE's competition here
OCUL vs TVTX Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, TVTX has a market cap of 2.9B. Regarding current trading prices, OCUL is priced at $7.97, while TVTX trades at $30.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas TVTX's P/E ratio is -55.84. In terms of profitability, OCUL's ROE is -0.72%, compared to TVTX's ROE of -0.79%. Regarding short-term risk, OCUL is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check TVTX's competition here
OCUL vs ARQT Comparison April 2026
OCUL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OCUL stands at 1.8B. In comparison, ARQT has a market cap of 2.9B. Regarding current trading prices, OCUL is priced at $7.97, while ARQT trades at $23.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OCUL currently has a P/E ratio of -5.68, whereas ARQT's P/E ratio is -181.96. In terms of profitability, OCUL's ROE is -0.72%, compared to ARQT's ROE of -0.10%. Regarding short-term risk, OCUL is less volatile compared to ARQT. This indicates potentially lower risk in terms of short-term price fluctuations for OCUL.Check ARQT's competition here